CN104547052A - Application in preparing medicine for resisting rheumatoid arthritis - Google Patents
Application in preparing medicine for resisting rheumatoid arthritis Download PDFInfo
- Publication number
- CN104547052A CN104547052A CN201510035007.1A CN201510035007A CN104547052A CN 104547052 A CN104547052 A CN 104547052A CN 201510035007 A CN201510035007 A CN 201510035007A CN 104547052 A CN104547052 A CN 104547052A
- Authority
- CN
- China
- Prior art keywords
- rhizoma corydalis
- corydalmine
- total alkaloids
- rheumatoid arthritis
- corydalis total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a new application of rhizoma corydalis, i.e., an application in preparing a medicine for resisting rheumatoid arthritis.
Description
Technical field
The present invention relates to the medical usage of active component in a kind of Chinese herbal medicine of extraction, be specifically related to Rhizoma Corydalis and Rhizoma Corydalis total alkaloids thereof and preparing the application prevented and treated in the medicine of rheumatoid arthritis.
Background technology
Rheumatoid arthritis (rheumatoid arthritis, RA) is a kind of autoimmune disease involving multi-joint synovitis pathological changes, whole world sickness rate about 1%, and its pathogenesis is complicated, by the impact of h and E factor.The basic lesion of RA is synovial cell proliferation, and backing layer thickens, multiple inflammatory cell infiltration, and the destruction of pannus formation and cartilage and osseous tissue, finally causes joint deformity and afunction.
The medicine being conventionally used to treatment RA clinically has three major types, i.e. NSAID (non-steroidal anti-inflammatory drug) (NSAID), disease hair conditioning antirheumatic (DMARD) and glucocorticoid medicine.In recent years, educational circles has more recognized and has adopted DMARD and NSAID or glucocorticosteroidsin in combination treatment to be a kind of ideal RA therapeutic strategies early.Methotrexate is an older NSAID (non-steroidal anti-inflammatory drug), is the solvent of current most scheme of combination drug therapy.Because traditional NSAIDs is effective slowly and have stronger side reaction, toleration is not good, is difficult to life-time service, and the sickness rate of the caused drug-induced disease for the treatment of is higher.Therefore, be necessary to find antirheumatic safely and efficiently further.
RA in modern medicine, rheumatic fever, neuralgia, facial paralysis, myositis, gout etc. all can carry out determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs by arthromyodynia.About " arthromyodynia ", in Huangdi's Internal Classics, just have that " wet three gas of wind and cold are mixed extremely, combined into numbness, its migratory BI-syndrome caused mainly by pathogenic wind, BI-syndrome caused mainly by pathogenic cold being called painful BI, dampness victor be damp arthralgia also " record, Zhang Zhongjing is called in treatise on Febrile Diseases " severe and migratory arthralgia ", and provide treatment prescription, as Ramuli Cinnamomi and Aconiti Praeparatae Decoction, Radix Glycyrrhizae et Radix Aconiti Lateralis Preparata Decoction etc., the medicine that kind more than 70 treats arthromyodynia is recorded in the pharmacy monograph Shennong's Herbal of China's earliest extant, current research only have the Radix Paeoniae Alba, Radix Salviae Miltiorrhizae, Fructus Corni and Flos Chrysanthemi etc. are several, other rarely have report, so the natural drug for the treatment of RA has potentiality to be exploited.
Rhizoma Corydalis is the dry tuber of Papaveraceae (Papaveraeeae) Corydalis (Corydalis) plant Rhizoma Corydalis (Corydalis yanhusuo W.T.Wang), is one of famous " eight Zhe's ".Rhizoma Corydalis has another name called Rhizoma Corydalis, corydalis tuber, rhizoma corydalis, Rhizoma Corydalis, taste acrid, bitter, warm, returns liver, spleen channel, has effect of promoting blood circulation to remove blood stasis, promoting the circulation of QI to relieve pain.Rhizoma Corydalis begins to be loaded in supplement to the Herbal, in the application of China's medicine and pharmacology, the history of more than 2,000 year is had as traditional analgesic and drug for invigorating blood circulation and eliminating stasis, ancient times and modern Chinese medicine Rhizoma Corydalis are mainly used in all pain cards of stagnation of QI-blood, cure mainly obstruction of qi in the chest and cardialgia, epigastric pain, lumbago, colicky, dysmenorrhea, amenorrhea, the stagnant stomachache of the stasis of blood in puerperal, traumatic injury etc.
Summary of the invention
The invention provides the novelty teabag of Rhizoma Corydalis and Rhizoma Corydalis total alkaloids thereof, the purposes namely in the medicine preparing resisting rheumatoid arthritis.
Present invention also offers a kind of pharmaceutical composition for preventing and treating rheumatoid arthritis.It is active component by Rhizoma Corydalis total alkaloids, adds the acceptable adjuvant of pharmacy and be prepared into conventional pharmaceutical preparation.
Rhizoma Corydalis total alkaloids is from Chinese crude drug Rhizoma Corydalis, extract the alkaloid obtained.
The preparation of Rhizoma Corydalis total alkaloids
Get Rhizoma Corydalis crude drug, add acid solution heating extraction.Merge extractive liquid, filters, concentrating under reduced pressure, and adjust ph, to alkalescence, is extracted with ethyl acetate then.Combined ethyl acetate layer, recycling design, to dry, obtains Rhizoma Corydalis total alkaloids.
The preferred preparation technology of Rhizoma Corydalis total alkaloids:
Get Rhizoma Corydalis crude drug 1-3kg, add 1-5% aqueous sulfuric acid 40-80 DEG C of heating extraction 2-4 time of 5-24L.Merge extractive liquid, filters, is evaporated to 2-9L, adds 1-10%NaOH solution in right amount, and adjust ph, to 9-11, extracts 2-4 time with ethyl acetate 1-16 L then.Combined ethyl acetate layer, recycling design, to dry, obtains Rhizoma Corydalis total alkaloids.
Get Rhizoma Corydalis crude drug 1-3kg, add 1-5% aqueous sulfuric acid 40-80 DEG C of heating extraction 2-4 time of 5-24L.Merge extractive liquid, filters, is evaporated to 2-9L, adds 1-10%NaOH solution in right amount, and adjust ph, to 9-11, extracts 2-4 time with ethyl acetate 1-16 L then.Combined ethyl acetate layer, recycling design is to dry, refining, obtains (-)-Corydalmine
Refining: above-mentioned Rhizoma Corydalis total alkaloids mixes sample with thick silica gel (100-200 order), through silica gel column chromatography, with dichloromethane-ethanol gradient elution (100:1 ~ 1:1).By dichloromethane-ethanol (100:1 ~ 1:1) elution fraction through the anti-phase ODS chromatographic isolation of C18 (with alcohol-water (5% ~ 100%) gradient elution), collect the alcohol elution of 25-55%, be separated (with alcohol-water (5% ~ 100%) gradient elution through polydextran gel Sephadex LH-20; Eluent flow rate 1ml/min), collect 45-85% ethanol elution fraction, after recycling design, be dissolved in methanol solution, recrystallization obtains compound (-)-Corydalmine.
(-)-Corydalmine content in Rhizoma Corydalis is very low, can prepare (-)-Corydalmine efficiently by the present invention.
Present invention also offers a kind of pharmaceutical composition for preventing and treating rheumatoid arthritis.It is active component by (-)-Corydalmine, adds the acceptable adjuvant of pharmacy and be prepared into conventional pharmaceutical preparation.
Present invention also offers a kind of pharmaceutical composition for preventing and treating rheumatoid arthritis.It is by (-)-Corydalmine 10-40mg, and berberine 0.1-5mg forms.
Described preparation is oral formulations.
The preparation of Rhizoma Corydalis total alkaloids tablet
Prescription: Rhizoma Corydalis total alkaloids 0.5-2g, starch 50-150g, dextrin 30-100g, calcium sulfate 30-200g, magnesium stearate 1-6g.
Method for making: get Rhizoma Corydalis total alkaloids, adds starch, dextrin, calcium sulfate, magnesium stearate, mix homogeneously, makes granule, tabletting, and sugar coating or film-coat, to obtain final product.
The preparation of (-)-Corydalmine tablet
Prescription: (-)-Corydalmine 10-40mg, starch 50-150g, dextrin 30-100g, calcium sulfate 30-200g, magnesium stearate 1-6g.
Method for making: get (-)-Corydalmine, adds starch, dextrin, calcium sulfate, magnesium stearate, mix homogeneously, makes granule, tabletting, and sugar coating or film-coat, to obtain final product.
The preparation of berberine (-)-Corydalmine tablet
Prescription: (-)-Corydalmine 10-40mg, berberine 0.1-5mg, starch 50-150g, dextrin 30-100g, calcium sulfate 30-200g, magnesium stearate 1-6g.
Method for making: get (-)-Corydalmine, berberine, adds starch, dextrin, calcium sulfate, magnesium stearate, mix homogeneously, makes granule, tabletting, and sugar coating or film-coat, to obtain final product.
Rhizoma Corydalis total alkaloids of the present invention, (-)-Corydalmine, inflammation-inhibiting, immunity moderation, the lymphocyte of remarkable lifting rats with arthritis, reduce neutrophil cell, reduce the content of inflammatory factor and inflammatory mediator in animal subject body, alleviated the arthritic symptom of rat by regulation and control inflammatory network.
Detailed description of the invention
The preparation of embodiment 1. Rhizoma Corydalis total alkaloids
Get Rhizoma Corydalis crude drug 1kg, add 2% aqueous sulfuric acid, 50 DEG C of heating extraction 4 times of 5L.Merge extractive liquid, filters, is evaporated to 4L, and add 5%NaOH solution in right amount, adjust ph to 10, extracts 4 times with ethyl acetate 2L then.Combined ethyl acetate layer, recycling design, to dry, obtains Rhizoma Corydalis total alkaloids.
Embodiment 2
Get Rhizoma Corydalis crude drug 1kg, add 2% aqueous sulfuric acid, 50 DEG C of heating extraction 4 times of 5L.Merge extractive liquid, filters, is evaporated to 4L, and add 5%NaOH solution in right amount, adjust ph to 10, extracts 4 times with ethyl acetate 2L then.Combined ethyl acetate layer, recycling design, to dry, obtains Rhizoma Corydalis total alkaloids.
Refining: above-mentioned Rhizoma Corydalis total alkaloids mixes sample with thick silica gel (200 order), through silica gel column chromatography, with dichloromethane-ethanol gradient elution (100:1 ~ 1:1).By dichloromethane-ethanol (10:1) elution fraction through the anti-phase ODS chromatographic isolation of C18 (with alcohol-water (5% ~ 100%) gradient elution), collect the alcohol elution of 35%, be separated (with alcohol-water (5% ~ 100%) gradient elution through polydextran gel Sephadex LH-20; Eluent flow rate 1ml/min), collect 65% ethanol elution fraction, after recycling design, be dissolved in methanol solution ,-4 DEG C of recrystallization obtain compound (-)-Corydalmine;
Embodiment 3
Get Rhizoma Corydalis crude drug 1kg, add 3% aqueous sulfuric acid, 70 DEG C of heating extraction 2 times of 6L.Merge extractive liquid, filters, is evaporated to 6L, and add 6%NaOH solution in right amount, adjust ph to 11, extracts 3 times with ethyl acetate 3 L then.Combined ethyl acetate layer, recycling design, to dry, obtains Rhizoma Corydalis total alkaloids 2.589g.
Refining: above-mentioned Rhizoma Corydalis total alkaloids mixes sample with thick silica gel (200 order), through silica gel column chromatography, with dichloromethane-ethanol gradient elution (100:1 ~ 1:1).By dichloromethane-ethanol (10:1) elution fraction through the anti-phase ODS chromatographic isolation of C18 (with alcohol-water (5% ~ 100%) gradient elution), collect the alcohol elution of 35%, be separated (with alcohol-water (5% ~ 100%) gradient elution through polydextran gel Sephadex LH-20; Eluent flow rate 1ml/min), collect 65% ethanol elution fraction, after recycling design, be dissolved in methanol solution ,-4 DEG C of recrystallization obtain compound (-)-Corydalmine;
The preparation of embodiment 4 berberine (-)-Corydalmine compositions: (-)-Corydalmine (-)-Corydalmine 20mg, berberine 1mg is mixed to get.
The preparation of embodiment 5 Rhizoma Corydalis total alkaloids tablet
Prescription: Rhizoma Corydalis total alkaloids 0.5g, starch 150g, dextrin 100g, calcium sulfate 200g, magnesium stearate 2g.
Method for making: get Rhizoma Corydalis total alkaloids, adds starch, dextrin, calcium sulfate, magnesium stearate, mix homogeneously, makes granule, tabletting, and sugar coating or film-coat, to obtain final product.
The preparation of embodiment 6 (-)-Corydalmine tablet
Prescription: (-)-Corydalmine 20mg, starch 150g, dextrin 100g, calcium sulfate 200g, magnesium stearate 2g.
Method for making: get (-)-Corydalmine, adds starch, dextrin, calcium sulfate, magnesium stearate, mix homogeneously, makes granule, tabletting, and sugar coating or film-coat, to obtain final product.
The preparation of embodiment 7 berberine (-)-Corydalmine tablet
Prescription: (-)-Corydalmine 20mg, berberine 1mg, starch 150g, dextrin 100g, calcium sulfate 200g, magnesium stearate 2g.
Method for making: get (-)-Corydalmine, berberine, adds starch, dextrin, calcium sulfate, magnesium stearate, mix homogeneously, makes granule, tabletting, and sugar coating or film-coat, to obtain final product.
Embodiment 8. Rhizoma Corydalis total alkaloids, (-)-Corydalmine, berberine are to the effect of the rats with arthritis that complete Freund's adjuvant is induced
Experimental technique
Rat is divided into groups, berberine (-)-Corydalmine group ((-)-Corydalmine 0.2mg/kg+ berberine 0.01 mg/kg), berberine group (berberine 0.01 mg/kg) that the (-)-Corydalmine group (0.2mg/kg) that Rhizoma Corydalis total alkaloids group (10 mg/kg), embodiment 2 that namely normal group, model group, positive drug group (diclofenac sodium 10 mg/kg), embodiment 1 prepare prepare, embodiment 4 prepare.Inflammation is caused at rat (except normal group) right back foot intradermal injection complete Freund's adjuvant.Gastric infusion from causing scorching second day, every day is administered once, each 1mL, continues 28 days.Evaluate rat cause scorching parapodum swelling degree and arthritis index in administration the 7th day, the 14th day, the 21st day and the 28th day respectively.Administration, after 28 days, gets blood under anesthesia, surveys peripheral blood lymphocyte and neutrophil cell.Separation of serum, surveys interleukin 6 in serum (IL-6), tumor necrosis factor (TNF-α) and prostaglandin 2(PGE2 with ELISA (ELISA)) content.Rat ankle joint is fixed in 10% formalin, routine paraffin wax embedding after 10%EDTA decalcification, film-making, and HE dyes, and by pathology professional diagosis, observation synovial tissue of joint, ossa articularia, cartilage tissue damage degree are carried out scoring and compared.
Experimental result
Rhizoma Corydalis total alkaloids is on the impact of rat paw edema degree and arthritis index
So that after rat foot volume and administration, the difference (Δ mL) of the sufficient volume of rat weighs the degree of rat paw edema before scorching.As shown in table 1, contrast with normal group, model group rats causes the scorching survey remarkable swelling of foot (P < 0.05).Compared with model group, Rhizoma Corydalis total alkaloids high low dose group all significantly suppresses rat articular swelling (P < 0.05).
1. Rhizoma Corydalis total alkaloids, (-)-Corydalmine cause the impact of scorching parapodum change in volume on rat
Group causes scorching parapodum change in volume (Δ mL)
7th day the 14th day the 21st day the 28th day
Normal group, 0.16 ± 0.03,0.15 ± 0.01,0.14 ± 0.04,0.15 ± 0.01
Model group, 2.52 ± 0.17,2.25 ± 0.23,2.31 ± 0.24,2.12 ± 0.35
Positive drug group, 1.23 ± 0.08,1.13 ± 0.15,0.98 ± 0.07,0.86 ± 0.15
Rhizoma Corydalis total alkaloids, 1.36 ± 0.13*, 1.23 ± 0.50*, 0.52 ± 0.08*, 0.47 ± 0.12*
(-)-Corydalmine, 0.83 ± 0.06*, 0.62 ± 0.03*, 0.56 ± 0.03*, 0.27 ± 0.12*
Berberine (-)-Corydalmine, 0.23 ± 0.01*, 0.37 ± 0.04*, 0.38 ± 0.03*, 0.21 ± 0.13*
* for comparing with model group, there is significant difference (P < 0.05)
Rat arthritis index adopts 5 points of general standards, and namely 0 is divided into without changing, and 1 is divided into anklebone portion to have swelling, and 2 are divided into anklebone portion and shank portion all to have swelling, and 3 are divided into swelling to extend to metatarsal portion, and 4 are divided into whole rear foot swelling obvious.The arthritis score best result of every only tested rat is 8 points, namely two metapedes scorings add and.As shown in table 2, compare with model group, the high low dose group of Rhizoma Corydalis total alkaloids all significantly reduces rat arthritis index (P < 0.05).
2. Rhizoma Corydalis total alkaloids, (-)-Corydalmine are on the impact of rat arthritis index
Group arthritis index
7th day, the 14th day, the 21st day, the 28th day
Model group, 5.23 ± 0.75,6.89 ± 0.56,5.56 ± 0.21,4.32 ± 0.60
Positive drug group, 4.12 ± 0.32,2.78 ± 0.69,2.14 ± 0.23,1.52 ± 0.53
Rhizoma Corydalis total alkaloids, 4.07 ± 0.16*, 4.32 ± 0.14*, 3.12 ± 0.35*, 2.22 ± 0.34*
(-)-Corydalmine, 3.21 ± 0.15*, 2.56 ± 0.27*, 2.65 ± 0.28*, 1.86 ± 0.26*
Berberine (-)-Corydalmine, 2.16 ± 0.13*, 1.98 ± 0.16*, 1.85 ± 0.16*, 1.73 ± 0.29*
Berberine, 5.04 ± 0.35,6.75 ± 0.12,5.26 ± 0.25,4.17 ± 0.42
* for comparing with model group, there is significant difference (P < 0.05)
Rhizoma Corydalis total alkaloids, (-)-Corydalmine are on the impact of Peripheral Lymphocytes of Rat and neutrophil cell
As shown in table 3, compare with normal group, model group rats peripheral blood lymphocyte significantly reduces (P < 0.05), and neutrophil cell significantly raises (P < 0.05).Rhizoma Corydalis total alkaloids high low dose group compares with model group, and peripheral blood lymphocyte all significantly raises, and neutrophil cell all significantly reduces.
Table 3. Rhizoma Corydalis total alkaloids is on the impact of Peripheral Lymphocytes of Rat and neutrophil cell
Group, lymphocyte count (10
6), neutrophil cell counting (10
6)
Normal group, 156.21 ± 5.52,45.75 ± 2.52
Model group, 79.22 ± 2.45,102.87 ± 6.02
Positive drug group, 115.52 ± 6.38,68.13 ± 1.96
Rhizoma Corydalis total alkaloids, 123.63 ± 7.26*, 36.17 ± 1.25*
(-)-Corydalmine, 136.6 ± 2.24*, 41.15 ± 1.58*
Berberine (-)-Corydalmine, 147.2 ± 1.37*, 43.27 ± 1.86*
Berberine, 76.48 ± 1.98,99.36 ± 6.52
* for comparing with model group, there is significant difference (P < 0.05)
(1) Rhizoma Corydalis total alkaloids, (-)-Corydalmine are on the impact of rat blood serum IL-6, TNF-α and PGE2 content
In model group rats serum, the content of IL-6, TNF-α and PGE2 compares significance and improves (P < 0.05) with normal group.In Rhizoma Corydalis total alkaloids extract, (-)-Corydalmine rat blood serum, the level of IL-6, TNF-α and PGE2 and model group contrast, and equal significance reduces (P < 0.05).。
Table 4. Rhizoma Corydalis total alkaloids is on the impact of rat blood serum IL-6, TNF-α and PGE2 content
Group, IL-6 (pg/mL), TNF-α (pg/mL), PGE2 (pg/mL)
Normal group, 35.78 ± 1.23,51.24 ± 1.89,31.48 ± 2.56
Model group, 78.14 ± 3.26,121.3 ± 5.31,98.45 ± 4.23
Positive drug group, 48.79 ± 1.75,87.56 ± 4.89,56.21 ± 3.75
Rhizoma Corydalis total alkaloids, 45.12 ± 2.46*, 78.12 ± 3.92*, 52.12 ± 1.52*
(-)-Corydalmine, 42.35 ± 1.26*, 63.16 ± 1.26*, 45.12 ± 1.57*
Berberine (-)-Corydalmine, 41.45 ± 1.31*, 57.25 ± 1.89*, 40.26 ± 1.16*
Berberine, 79.26 ± 3.78,123.1 ± 5.59,97.21 ± 4.56
* for comparing with model group, there is significant difference (P < 0.05)
(2) Rhizoma Corydalis total alkaloids, (-)-Corydalmine are on the impact of rat articular pathological change
Rat ankle joint is fixed in 10% formalin, routine paraffin wax embedding after 10%EDTA decalcification, film-making, and HE dyes, and by pathology professional diagosis, observation synovial tissue of joint, ossa articularia, cartilage tissue damage degree are carried out scoring and compared.According to each site morbidity light and heavy degree, be quantitatively 0 to 4 point successively.1 point (slightly), 2 points (moderate), 3 points (severe), 4 points (pole severe), 0 point (normal).Cumulative all marks, draw and often organize average mark.
Result shows, and the synovial membrane surface of normal rats is covered with 1-4 layer synovial cell, without obvious degeneration, necrosis, without hypertrophy.Joint facial bone and cartilaginous tissue are without degeneration, necrosis.Surrounding skin has no inflammatory reaction.
Synovial cell's moderate degeneration of model group rats, synovial tissue's moderate is congested, and inside have cell infiltration, inflammatory cell type is mainly mononuclear phagocyte and neutrophilic granulocyte.Have a large amount of cell infiltration in corium and subcutaneous tissue, inflammatory cell type is mainly mononuclear phagocyte, lymphocyte and a small amount of neutrophilic granulocyte.
Compare with model group, Rhizoma Corydalis total alkaloids, (-)-Corydalmine be ameliorate osteoarthritis pathological changes all significantly.
Table 5. Rhizoma Corydalis total alkaloids, (-)-Corydalmine are on the impact of rat articular pathological change
Group, animal number of elements, pathological change is marked
Normal group, 10,0.00 ± 0.00
Model group, 10,6.00 ± 0.36
Positive drug group, 10,1.89 ± 0.42
Rhizoma Corydalis total alkaloids, 10,1.42 ± 0.18*
(-)-Corydalmine, 10,1.19 ± 0.12*
Berberine (-)-Corydalmine, 10,1.02 ± 0.18*
Berberine, 10,6.03 ± 0.41
For comparing with model group, there is significant difference (P < 0.05)
Embodiment 9 thin layer chromatography:
Adsorbent: silica gel G thin layer precoated plate (Qingdao);
Developing solvent: ethyl acetate-n-butyl alcohol-ethanol-ammonia (10: 3: 1.5: 1: 1),
Embodiment 2 sample 1 μ L point plate,
Launch temperature room temperature, presaturation 15min before launching, exhibition distance 10cm,
Take out, dry, inspect under putting ultra-violet lamp (365nm).
Only there is unique speckle in 6.9 cm.
Embodiment 10 high performance liquid chromatography:
Chromatographic column take octadecylsilane chemically bonded silica as filler; Shimadzu liquid phase instrument
Mobile phase is acetonitrile-1% aqueous formic acid (20: 80 volume ratio), isocratic elution;
Flow velocity 1.0mL/min; Column temperature 30 DEG C; Determined wavelength 280nm.
Under these conditions, draw respectively and remove embodiment 2 sample (mobile phase solution) 10 μ L, inject high performance liquid chromatograph and analyze,
1 chromatographic peak in this collection of illustrative plates, appearance time 18.36 minutes, peak area 456936.35AU.
Claims (7)
1. a pharmaceutical applications for Rhizoma Corydalis, is characterised in that Rhizoma Corydalis is preparing the application in resisting rheumatoid arthritis medicine.
2. a pharmaceutical applications for Rhizoma Corydalis total alkaloids, is characterised in that Rhizoma Corydalis total alkaloids is preparing the application in resisting rheumatoid arthritis medicine.
3. according to the purposes described in claim 1, it is characterized in that: described (-)-Corydalmine derives from Rhizoma Corydalis total alkaloids.
4. according to the purposes described in claim 1, it is characterized in that: get Rhizoma Corydalis crude drug, add hydrochloric acid solution heating extraction, merge extractive liquid, filter, concentrating under reduced pressure, regulates pH value to alkalescence, is then extracted with ethyl acetate, combined ethyl acetate layer, recycling design is to dry, refining, obtains (-)-Corydalmine.
5. treat a pharmaceutical composition for rheumatoid arthritis, it is characterized in that: be active component by the (-)-Corydalmine of effective dose, add that the adjuvant of pharmacy or complementary composition are prepared into conventional pharmaceutical preparation.
6. according to the pharmaceutical composition described in claim 5, it is characterized in that: described preparation is oral formulations.
7. treat a pharmaceutical composition for rheumatoid arthritis, it is characterized in that: be active component by the (-)-Corydalmine of effective dose, berberine, add that the adjuvant of pharmacy or complementary composition are prepared into conventional pharmaceutical preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510035007.1A CN104547052A (en) | 2015-01-25 | 2015-01-25 | Application in preparing medicine for resisting rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510035007.1A CN104547052A (en) | 2015-01-25 | 2015-01-25 | Application in preparing medicine for resisting rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104547052A true CN104547052A (en) | 2015-04-29 |
Family
ID=53064824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510035007.1A Pending CN104547052A (en) | 2015-01-25 | 2015-01-25 | Application in preparing medicine for resisting rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547052A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115414368A (en) * | 2022-10-25 | 2022-12-02 | 北京远方通达医药技术有限公司 | Medicine composition for treating traumatic injury and application thereof |
-
2015
- 2015-01-25 CN CN201510035007.1A patent/CN104547052A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 宋洋等: "生物转化合成左旋紫堇达明诱导剂筛选及优化", 《中国野生植物资源》 * |
| 王凤云等: "生物碱治疗类风湿性关节炎的研究进展", 《中药药理与临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115414368A (en) * | 2022-10-25 | 2022-12-02 | 北京远方通达医药技术有限公司 | Medicine composition for treating traumatic injury and application thereof |
| CN115414368B (en) * | 2022-10-25 | 2023-07-28 | 北京远方通达医药技术有限公司 | Pharmaceutical composition for treating traumatic injury and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006056117A1 (en) | Herbal medical preparation for the treatment of arthritis | |
| KR102123972B1 (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
| Du et al. | The potential of traditional Chinese medicine in the treatment and modulation of pain | |
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN101829232B (en) | Preparation method of traditional Chinese medicine composition for treating thromboangiitis obliterans | |
| CN102380015B (en) | Medicinal composition for treating rheumatoid arthritis and preparation method and application thereof | |
| CN101947276A (en) | Chinese medicinal composition for treating rheumatic arthritis | |
| WO2021093087A1 (en) | Traditional chinese medicine composition having effect of improving cognition, preparation method therefor, and traditional chinese medicine preparation | |
| CN100522183C (en) | Earthworm acidic-part medicine for treating cough asthma disease and preparing method | |
| CN103071134B (en) | External preparation for treating rheumatic arthrodynia and traumatic pain and swelling and preparation method thereof | |
| CN115770279B (en) | Traditional Chinese medicine composition for treating chronic lower limb vein diseases, decoction and preparation thereof | |
| CN104547052A (en) | Application in preparing medicine for resisting rheumatoid arthritis | |
| CN1973853B (en) | Hemostatic and analgetic medicine composition and its preparation process | |
| CN104547053A (en) | Application of rhizoma-corydalis extract in preparing medicine for treating rheumatoid arthritis | |
| CN107669751A (en) | A kind of clarification process and method of quality control of the pharmaceutical composition that there is treatment red blood trace on face to act on | |
| CN103768327B (en) | A kind of pure component Chinese medicine preparation and preparation technology treating functional dyspepsia | |
| CN104547055A (en) | Application of rhizoma corydalis in inhibiting advanced tumor pain | |
| CN1919273B (en) | Chinese medicinal composition for treating headache | |
| CN104510781A (en) | Application of rhizoma corydalis to resistance to tumor pain | |
| CN104095904A (en) | Medical composition for treating bile related diseases, and preparation method and application thereof | |
| CN104095912A (en) | Traditional Chinese medicine formula for treating rheumatism bone disease and preparation method of Chinese patent medicine of traditional Chinese medicine formula | |
| Jia et al. | Herbal medicine Gan‑fu‑kang downregulates Wnt/Ca2+ signaling to attenuate liver fibrogenesis in vitro and in vivo | |
| CN102940621A (en) | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis | |
| CN102772548B (en) | A kind of preparation method for the treatment of the Chinese medicine composition of lupus erythematosus | |
| CN103585275B (en) | Be used for the treatment of the preparation method and application of Chinese medicine composition and the Chinese patent drug of rheumatism bone disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150429 |